Existing investor Boehringer Ingelheim Venture Fund took part in a round that will help advance NBE's lead antibody-drug conjugate cancer treatment in clinical trials.
Switzerland-based antibody-drug conjugate (ADC) developer NBE Therapeutics has completed a CHF20m ($20.5m) series B round featuring pharmaceutical company Boehringer Ingelheim’s corporate venturing unit, Boehringer Ingelheim Venture Fund.
Financial services firm PPF Group led the round, which included NBE’s existing backers and a new, undisclosed private investor. Jan Hennecke, chief business officer of PPF’s biotech subsidiary Sotio, will join NBE’s board of directors in conjunction with the round.
NBE is working on ADCs that will be used to combat cancer. It…
